The AAIC 2026 Swedish study showed a blood test can help primary-care doctors diagnose Alzheimer's accurately in people with mild cognitive impairment, raising practical questions about access, cost, and follow-up. Mild cognitive impairment, or MCI, means noticeable memory or thinking changes that do not block daily life and often prompts testing for early Alzheimer's. Researchers tested a blood assay that measures amyloid-beta plus phosphorylated tau proteins linked to Alzheimer's disease. The work enrolled more than 1,300 patients evaluated for MCI or dementia with 165 physicians across primary and specialty care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the Swedish study test?
- How accurate were primary-care doctors with the test?
- How did results change diagnosis and care?
- Can you get the test, and what does it cost?
- Who is it for, and what should you ask next?
What did the Swedish study test?
Neurologist Sebastian Palmqvist of Lund University led the real-world study reported at AAIC 2026 in London on July 14, 2026. As described in the Alzheimer's Association AAIC release 2026 AAIC study summary, the team enrolled people already being evaluated for MCI or dementia in routine primary and specialty clinics.
The tested assay measured blood amyloid-beta plus phosphorylated tau, two disease proteins tied to Alzheimer's pathology. Doctors made a working diagnosis before testing, then reviewed the blood result and reassessed accuracy against standard clinical evaluation.
How accurate were primary-care doctors with the test?
After seeing blood results, primary-care physicians reached about 90% diagnostic accuracy, up from roughly 62-65% before testing. That performance nearly matched dementia specialists at about 90-94%.
The test had greatest value in ruling out Alzheimer's. A negative result gave primary-care doctors stronger footing to look for other causes of memory change and direct referrals more selectively.
How did results change diagnosis and care?
Physicians changed the working diagnosis in about one-third of patients after reviewing the blood result. They changed planned follow-up care or examinations in more than half.
For a person with MCI, that can mean a faster shift from watchful waiting to targeted next steps. For another, a low-risk blood result can reduce urgency for invasive testing and focus care on sleep, medications, mood, and vascular risks.
Can you get the test, and what does it cost?
In the United States, the Alzheimer's Association news notice reports FDA clearance of C2N's PrecivityAD2 on Aug. 20, 2026, for adults age 40 and older with cognitive symptoms FDA clearance announcement.
The clearance covers use alongside clinical assessment to detect amyloid pathology, not use alone. Cost remains a barrier without routine insurance coverage. Reporting on the company price cites about $1,250 list price, with assistance lowering eligible out-of-pocket cost to $25-$400 Scientific American cost reporting.
- Blood test: about $1,250 list, often $25-$400 with eligible assistance
- Amyloid PET scan: about $5,000
- Spinal-fluid testing: about $800-$1,000
Who is it for, and what should you ask next?
The tests are validated for people already having cognitive symptoms, not for healthy screening. According to the Mayo Clinic Press guide, positive or intermediate results commonly require specialist referral and confirmatory PET or spinal-fluid testing Mayo Clinic Press explainer. If you have MCI and discuss testing, ask focused follow-up questions at the same visit: Bring a symptom timeline, full medication list, and a family member to record the plan.
- What does my amyloid and p-tau score and its predictive value mean for me?
- Do I need PET or spinal-fluid confirmation?
- Should I see a dementia specialist, and how soon?
- How does the result affect treatment eligibility and care planning?
You Might Also Like
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: Access, Cost, and Follow-Up Questions for People With Mild Cognitive Impairment
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
